Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Core Insights - Glucotrack, Inc. is preparing to file an Investigational Device Exemption (IDE) for its novel continuous blood glucose monitoring (CBGM) technology, aiming to launch clinical trials in the U.S. in the second half of 2026 [1][2] Corporate Highlights - The company made significant progress in 2025, including the issuance of three new patents by the USPTO, which enhances its competitive position and intellectual property portfolio [2][5] - A long-term multicenter feasibility study for the CBGM product was initiated in Australia [4] - A private placement raised approximately $4.0 million, which will be used for working capital and general corporate purposes [5] - The company appointed Dr. Usman Latif to its clinical advisory team, bringing expertise in pain management and diabetic neuropathy [5] Product and Clinical Development - The first phase of the clinical study provided insights into product improvements and eligibility criteria, leading to expedited discussions with the FDA regarding the planned U.S. clinical trial program [6] - The company presented at the 2025 Diabetes Technology Meeting, emphasizing the integration of continuous glucose monitoring with existing implantable technologies [6] Financial Results - Research and development expenses for 2025 were $9.8 million, a slight increase from $9.5 million in 2024, primarily due to heightened product design and development activities [8] - General and administrative expenses rose to $6.3 million in 2025 from $5.1 million in 2024, mainly due to increased professional fees and personnel costs [9] - The net loss for 2025 was $19.4 million, a decrease from $22.6 million in 2024, attributed to non-cash losses recognized in the prior year [10] - Cash and cash equivalents increased to $7.4 million as of December 31, 2025, compared to $5.6 million in 2024, supported by financing activities [11] Anticipated Milestones - The company plans to submit its IDE to the FDA in the second quarter of 2026 to initiate a human clinical feasibility study of the CBGM product [13] - Additional clinical data will be presented at industry conferences to demonstrate the safety and accuracy of the CBGM product [13] - The company aims to expand its advisory boards with experts in endocrinology and cardiology to enhance its diabetes management solutions [13]